Navigation Links
Combination therapy improves AIDS-related lymphoma outcome

Combining aggressive HIV therapy and chemotherapy significantly improves the survival rates of HIV-positive men and women treated for lymphoma, according to a new study.

Published in the April 1, 2006 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society, the study reveals that combination therapy showed the greatest benefit for HIV patients suffering from aggressive malignant non-Hodgkin's lymphoma. This benefit was most pronounced in HIV patients without severely impaired immune functions. These so-called "standard risk" patients responded as well to therapy and survived as long as lymphoma patients without HIV.

Lymphomas are cancers of the immune system's white blood cells. They are treated with chemotherapy, often consisting of a multi-drug regimen using cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). People with HIV, a virus that depletes integral, specialized white cells called CD-4 cells, are at increased risk of developing lymphomas, particularly aggressive, fast-growing non-Hodgkin type lymphomas. These are called "AIDS-related lymphomas" (ARL) and generally have a poorer prognosis than non-HIV-related lymphomas. Highly active antiretroviral therapy (HAART) revolutionized care of HIV-positive men and women. It not only improves laboratory indicators, such as increased CD-4 cells and reduced viral loads, but also significantly improves survival and delays the onset of AIDS and AIDS-related cancers, including lymphomas.

With the lack of study data to show the efficacy of maintaining HIV-positive patients on HAART while they are treated with chemotherapy for ARL, oncologists are hesitant to expose HIV patients to hypothetical drug toxicities related to combining the therapies. Researchers led by Rudolf Weiss, M.D., of Specialist Practice for Hematology, Oncology and Infectious Diseases
'"/>

Source:John Wiley & Sons, Inc.


Page: 1 2

Related biology news :

1. Combination therapy boosts effectiveness of telomere-directed cancer cell death
2. Combination therapy leads to partial recovery from spinal cord injury in rats
3. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
4. Combination therapy shows promising results in patients with advanced lung cancer
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Columbia research lifts major hurdle to gene therapy for cancer
7. Gene therapy converts dead bone graft to new, living tissue
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. New therapy for HIV/AIDS eliminates needles and excessive toxicity

Post Your Comments:
(Date:11/4/2009)...TY, Calif., Oct. 20 DigitalPersona...ntication solutions, today announced that WAND Cor...) software for quick-service restaurants, has inte...n POS and Classic POS solutions. WAND,s quick-serv...o boost cashier accountability and deter unauthori...
(Date:11/4/2009)...Calif., Oct. 23 GenVault Corporati...nagement for genomic discovery, medicine and ident...., GenVault,s President and CEO, will be presentin...n October 26th and 27th in La Jolla, CA. ,, Dur...verview of the company together with recent custom...
(Date:11/4/2009)...HILL Scientists at the University of North Caroli...rsity of California, San Francisco have developed ...ew target diseases for existing drugs. , The res...pares how similar the structures of all known drug...-- known as ligands -- of disease targets within t...
Breaking Biology News(10 mins):WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 3GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Study points to new uses, unexpected side effects of already existing drugs 2LEDs To Completely Replace Halogen Lights in the European Surgical Market By 2014 5330 1LEDs To Completely Replace Halogen Lights in the European Surgical Market By 2014 5330 2LEDs To Completely Replace Halogen Lights in the European Surgical Market By 2014 5330 3Chris Jensen Medical Center Saves Estimated 24600 000 in First Year of Safe Patient Handling 5328 1Chris Jensen Medical Center Saves Estimated 24600 000 in First Year of Safe Patient Handling 5328 2Chris Jensen Medical Center Saves Estimated 24600 000 in First Year of Safe Patient Handling 5328 3CVS pharmacys Transportation Operations Receives Two National Safety Awards 5326 1CVS pharmacys Transportation Operations Receives Two National Safety Awards 5326 2
... National Academy of Sciences , Yale researchers u... huge amounts of data on physical characteristics ...n habitats and metabolic activity in marine micro-...ed detail how environment influences molecular cha...bbed "metagenomics" progresses, scientists might b...
...threats to biodiversity and in many cases they hav... For their effective management it is important to...highest risk of being invaded. , The first map of...ion was published in the Wiley-Blackwell journal ...team of Czech, Spanish and British plant ecologist...
...your response to a radiological incident? How will... take care of us? How do we even know if we are ex...ll be addressed at the 42nd Midyear Topical Meetin...take place January 31-Feb 3, 2009 in San Antonio, ...The topic is "Recent Advances in Planning and Resp...
Other Biology News:Mixing genomics and geography yields insights into life and environment 242nd Mid-year Topical Meeting of the Health Physics Society 2
(Date:11/6/2009)..., Mass., Nov. 6 Myriant Technologi...loper and manufacturer of renewable bio-chemicals...chnology provider Uhde GmbH, one of the world,s le...nounced an alliance for the engineering, procureme...Succinic Acid plants based on renewable feedstocks...
(Date:11/6/2009)...D, Calif., Nov. 6 Intarcia Therape...ts ITCA 650 (DUROS® continuous delivery of ex...tes at the Ninth Annual Diabetes Technology Meetin...ewscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) ,... Via ITCA 650 Lowers Plasma Glucose, HbA1c and Red...
(Date:11/5/2009)...PANY, N.J., Nov. 5 DSM Pharmaceuti...nufacturing alliance with Galenix, Saint Jean D,Il...rcial scale manufacturing partner for Galenix comm...alenix will collaborate on business development op...hnologies, based on the strength of Galenix in dru...
(Date:11/5/2009)...OK, N.Y., Nov. 5 BioSpec...armaceutical company developing first-in-class col...cial results for the third quarter ended September...n September of this year, the FDA,s Arthritis Advi...of 12-0, the approval of XIAFLEX(TM) for the treat...
Breaking Biology Technology:Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5
...ELPHIA, July 31 /PRNewswire-FirstCall/,-- Shire Li...ty,biopharmaceutical company announces results for...inancial Highlights, - Product sales up 40% to $7...4% to $409m - New product sales(1) $243m, 34% of ... to $776m - US GAAP earnings per ADS: loss $0.44 ...
... Health, a,global provider of products and service...th care, today announced a three-year agreement wi... pharmacy benefit managers,to serve as its primary...maceuticals, effective August 1., Prime Therapeut... drug,spend in 2007, and currently serves approxim...
...ook, MELVILLE, N.Y., July 31 Gentiva Health,Serv...provider of,comprehensive home health services, to... double-digit increases in Medicare revenues and a...(Logo: http://www.newscom.com/cgi-bin/prnh/200603...quarter ended June 29, 2008 included:, -- A 13% i...
Other Biology Technology:Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 2Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 3Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 4Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 5Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 6Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 7Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 8Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 9Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 10Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 11Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 12Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 13Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 14Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 15Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 16Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 17Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 18Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 19Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 20Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 21Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 22Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 23Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 24Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 25Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 26Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 27Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 28Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 29Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 30Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 31Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 32Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade. 33Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement 2Gentiva Reports Strong Second Quarter led by Home Health Segment 2Gentiva Reports Strong Second Quarter led by Home Health Segment 3
Mouse Anti-Mouse Qa.m8 Monoclonal Antibody, Unconjugated, Clone 5035-24.1 from CEDARLANE Laboratories Limited
...s at the 9, 10, 12, and 13 positions. It is intend...ication of 13(S)-HODE by GC- or LC-mass spectromet...ic acid with plant and mammalian lipoxygenases. It...ells to the endothelium at concentrations around 1...
pcDNA4/His A B & C from Invitrogen
Adaptor Hind III - Sma I from Takara Mirus Bio
Biology Products: